TP53 and plasma cell myeloma: Approximately 70–90% of p53 mutations are found in PDAC, and it is believed that if a therapeutic drug for p53 was available, it would have a great effect on PDAC.2,19 Recently, there have been reports of agents that restore p53 function, showing effectiveness in oesophageal squamous cell carcinoma, osteosarcoma, multiple myeloma, lung cancer, breast cancer, and colon cancer in vitro.20–24